208 related articles for article (PubMed ID: 32593959)
1. Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab.
Guevara C; Villa E; Cifuentes M; Naves R; Grazia J
Mult Scler Relat Disord; 2020 Sep; 44():102314. PubMed ID: 32593959
[No Abstract] [Full Text] [Related]
2. Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment.
Haas J; Würthwein C; Korporal-Kuhnke M; Viehoever A; Jarius S; Ruck T; Pfeuffer S; Meuth SG; Wildemann B
Front Immunol; 2019; 10():1204. PubMed ID: 31214176
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID.
Fiorella C; Lorna G
Mult Scler Relat Disord; 2020 Nov; 46():102447. PubMed ID: 32835901
[TBL] [Abstract][Full Text] [Related]
4. Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
Mult Scler; 2019 Dec; 25(14):1942-1945. PubMed ID: 30403365
[TBL] [Abstract][Full Text] [Related]
5. Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report.
Lucchini M; Bianco A; Del Giacomo P; De Fino C; Nociti V; Mirabella M
Mult Scler Relat Disord; 2020 Sep; 44():102323. PubMed ID: 32593961
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab.
Aguirre C; Meca-Lallana V; Sánchez P; Vivancos J
Mult Scler Relat Disord; 2019 Oct; 35():270-271. PubMed ID: 31442904
[TBL] [Abstract][Full Text] [Related]
7. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
Baker D; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 will change MS care forever - No.
Preziosa P; Rocca MA; Filippi M
Mult Scler; 2020 Sep; 26(10):1149-1151. PubMed ID: 32567471
[No Abstract] [Full Text] [Related]
9. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.
Meca-Lallana V; Aguirre C; Beatrizdel Río ; Cardeñoso L; Alarcon T; Vivancos J
Mult Scler Relat Disord; 2020 Sep; 44():102306. PubMed ID: 32585617
[TBL] [Abstract][Full Text] [Related]
10. Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
Guevara C; Villa E; Rosas CS; Diaz V; Naves R
Mult Scler Relat Disord; 2020 Aug; 43():102224. PubMed ID: 32464582
[No Abstract] [Full Text] [Related]
11. Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab.
Matías-Guiu J; Montero-Escribano P; Pytel V; Porta-Etessam J; Matias-Guiu JA
Mult Scler Relat Disord; 2020 Sep; 44():102297. PubMed ID: 32554284
[TBL] [Abstract][Full Text] [Related]
12. Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.
Midaglia L; Gratacòs M; Caronna E; Raguer N; Sastre-Garriga J; Montalban X; Tintoré M
Neurology; 2018 Sep; 91(13):622-624. PubMed ID: 30143565
[No Abstract] [Full Text] [Related]
13. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
Ceronie B; Jacobs BM; Baker D; Dubuisson N; Mao Z; Ammoscato F; Lock H; Longhurst HJ; Giovannoni G; Schmierer K
J Neurol; 2018 May; 265(5):1199-1209. PubMed ID: 29550884
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab depletion failure can occur in multiple sclerosis.
Dubuisson N; Baker D; Kang AS; Pryce G; Marta M; Visser LH; Hofmann WE; Gnanapavan S; Giovannoni G; Schmierer K
Immunology; 2018 Jun; 154(2):253-260. PubMed ID: 29247512
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a safety protocol for the administration of treatments in multiple sclerosis during the SARS-CoV-2 pandemic.
Meca-Lallana V; Aguirre C; Cardeñoso L; Alarcon T; Figuerola-Tejerina A; Del Río B; Álvarez MR; Vivancos J
Mult Scler Relat Disord; 2020 Sep; 44():102244. PubMed ID: 32544863
[No Abstract] [Full Text] [Related]
16. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
17. The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis.
Rolla S; Maglione A; De Mercanti SF; Clerico M
Cells; 2020 Jun; 9(6):. PubMed ID: 32503344
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab and prescription medication use in the MS population.
Chertcoff A; Ng HS; Zhu F; Zhao Y; Kingwell E; Tremlett H
Mult Scler Relat Disord; 2020 Jul; 42():102086. PubMed ID: 32403069
[TBL] [Abstract][Full Text] [Related]
19. Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
Aguirre C; Meca-Lallana V; Barrios-Blandino A; Del Río B; Vivancos J
Mult Scler Relat Disord; 2020 Sep; 44():102250. PubMed ID: 32531754
[TBL] [Abstract][Full Text] [Related]
20. B cell depletion therapy resulting in sustained remission of severe autoimmune complications following Alemtuzumab treatment of Multiple Sclerosis.
Massey J; Barnett Y; Curnow J; Sutton I
Mult Scler Relat Disord; 2019 Oct; 35():100-103. PubMed ID: 31357122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]